Defective Product Injury Case Study: Power Tool Accident, Hand Surgery, and Pharmacy Lien

James Wong — Founder & CEO, LienScripts | March 4, 2026 | 8 min read

A defective power tool caused a severe hand injury requiring multiple surgeries and 13 months of medication management. This case study examines how a pharmacy lien covered the pharmaceutical treatment while the product liability claim against the manufacturer proceeded.

Defective product injuries — particularly those involving power tools, machinery, and industrial equipment — can cause devastating hand and upper extremity injuries that require multiple surgeries, extensive rehabilitation, and prolonged pharmaceutical management.

Note: This is a fictionalized case study based on composite facts. Names and identifying details are not real. The clinical details represent typical medication patterns for this injury type.

• Product liability claims against manufacturers involve strict liability, design defect, and failure-to-warn theories
• Hand injuries from power tool defects require staged surgical repairs and extended pharmaceutical management for nerve regeneration
• A 13-month pharmacy lien documented the multi-surgery recovery including nerve repair, tendon reconstruction, and chronic neuropathic management
• LienScripts' MERIT (Medication Evaluation & Rationale for Injury Treatment) report connected the medication regimen to the specific product defect
• The manufacturer argued misuse; the pharmaceutical record documented injuries consistent with a guard failure, not operator error

Case Background

Patient: Robert T. (name changed), 48-year-old male, cabinet maker

Incident: Robert was using a table saw manufactured by a major power tool company. The saw's blade guard had a design defect — the anti-kickback pawls failed to engage properly, allowing a piece of hardwood to kick back and pull Robert's right hand into the spinning blade. The saw lacked the flesh-detection safety technology that was available and commercially viable at the time of manufacture.

Injuries: Near-complete amputation of the right index finger (replanted surgically), laceration of the flexor digitorum profundus tendon in the middle finger, digital nerve transections in the index and middle fingers, and a comminuted fracture of the second metacarpal.

Initial Treatment: Robert was transported to a hand surgery center of excellence. The replantation of the index finger was performed as an emergent microsurgical procedure. The flexor tendon laceration was repaired primarily, and the digital nerves were repaired using microsurgical technique. The metacarpal fracture was stabilized with K-wires.

Insurance Situation: Robert was self-employed with a high-deductible health plan. The plan covered the initial emergency surgery but applied the full deductible, and subsequent surgeries and medications required extensive prior authorization.

Attorney: Victoria L. (name changed), a product liability attorney.

Legal Theory

Victoria filed a product liability claim based on three theories:

Design defect. The table saw lacked commercially available flesh-detection technology that would have stopped the blade within milliseconds of skin contact, preventing the injury entirely.

Manufacturing defect. The anti-kickback pawls had a tolerance error that prevented proper engagement, allowing the kickback that initiated the injury.

Failure to warn. The saw's safety warnings did not adequately convey the risk of kickback injury or the availability of aftermarket safety devices.

The Pharmacy Lien: 13 Months of Coverage

Victoria enrolled Robert in the LienScripts pharmacy lien program after the initial replantation surgery. With multiple staged surgeries planned and insurance prior authorization creating delays, the lien program ensured uninterrupted medication access.

Medication Timeline

Post-Replantation Phase: Months 1-3

Aspirin 325mg daily for anti-platelet therapy to support microvascular blood flow in the replanted finger. Replantation success depends on maintaining blood flow through the microsurgically repaired vessels.

Heparin 5000 units subcutaneous twice daily for 5 days, transitioning to aspirin, for initial anti-coagulation to prevent thrombosis in the repaired vessels.

Oxycodone 10mg every 6 hours for acute post-microsurgical pain. Hand replantation produces severe pain during the revascularization period.

Cephalexin 500mg four times daily for wound infection prophylaxis. Open hand injuries with contamination (sawdust, wood debris) carry significant infection risk.

Gabapentin 300mg three times daily was initiated early — at week 2 — for prophylactic neuropathic pain management. Digital nerve repairs frequently produce neuropathic symptoms during the regeneration period, and early gabapentinoid initiation can reduce the severity of subsequent neuropathic pain.

Second Surgery and Recovery: Months 4-7

Robert underwent a second surgery at month 4 — a staged flexor tendon reconstruction using a silicone rod (Hunter rod) in the middle finger, preparing for a subsequent tendon graft.

Oxycodone 5mg every 8 hours for the second post-surgical period, with documented taper over three weeks.

Celecoxib 200mg daily as the primary anti-inflammatory agent during the rehabilitation phase.

Gabapentin titrated to 600mg three times daily as neuropathic symptoms intensified during nerve regeneration. The Tinel's sign (tingling at the nerve repair site) was advancing distally — a positive sign of nerve regeneration but accompanied by significant neuropathic pain.

According to James Wong, PharmD, founder of LienScripts, "Hand injury cases with nerve repairs produce some of the most clinically detailed pharmacy records. The nerve regeneration process takes months, and the pharmacy record captures the dose titrations, medication additions, and clinical responses that document the regeneration timeline. This is evidence that no other source provides."

Topical lidocaine 5% cream applied to the hand for localized nerve pain management during occupational therapy sessions.

Third Surgery and Long-Term Management: Months 8-13

The third surgery — a palmaris longus tendon graft to replace the Hunter rod in the middle finger — was performed at month 8.

Pregabalin 75mg twice daily was added at month 9 when gabapentin alone was insufficient for the neuropathic pain. The dual gabapentinoid approach reflected the severity of the multi-digit nerve injuries.

Duloxetine 30mg daily, titrated to 60mg for combined neuropathic pain and the depression and anxiety that had developed. Robert's livelihood as a cabinet maker depended on hand function, and the uncertain recovery was causing severe psychological distress.

Cyclobenzaprine 5mg at bedtime for the hand and forearm muscle tension from intensive occupational therapy.

By month 13, Robert had regained partial function in the replanted index finger and restored middle finger flexion through the tendon graft. His hand surgeon documented permanent sensory deficits, reduced grip strength, and limitations on fine motor tasks.

How Pharmacy Documentation Supported the Case

The manufacturer argued that Robert misused the saw by removing the blade guard. Victoria's response included:

• The pharmaceutical record documented injuries consistent with a kickback mechanism (guard in place but pawls malfunctioning), not a direct blade contact from guard removal
• The replantation medications (anti-platelet therapy, anticoagulants) documented an injury pattern — near-amputation with vessel repair — that was inconsistent with the manufacturer's misuse theory
• The MERIT report provided a pharmacist's clinical narrative connecting the 13-month, three-surgery medication regimen to the specific defect mechanisms

Settlement Outcome

The case settled with the manufacturer's product liability insurer contributing the primary settlement and the retailer's policy contributing an additional amount. The 13-month pharmaceutical record — spanning three surgeries, nerve regeneration, and permanent functional limitations — was central to establishing damages.

Related Resources

• What Is a MERIT Report?
• Gabapentin for Neuropathic Pain
• Defective Product and Pharmacy Liens